D
D. Lawrence Wickerham
Researcher at Allegheny Health Network
Publications - 13
Citations - 6164
D. Lawrence Wickerham is an academic researcher from Allegheny Health Network. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 11, co-authored 13 publications receiving 5762 citations. Previous affiliations of D. Lawrence Wickerham include Allegheny College & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Soonmyung Paik,Gong Tang,Steven Shak,Chungyeul Kim,Joffre B. Baker,Wanseop Kim,Maureen T. Cronin,Frederick L. Baehner,Drew Watson,John Bryant,Joseph P. Costantino,Charles E. Geyer,D. Lawrence Wickerham,Norman Wolmark +13 more
TL;DR: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Journal ArticleDOI
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,James L. Wade,Richard G. Margolese,Scott M. Lippman,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +17 more
TL;DR: Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Journal ArticleDOI
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27
Harry Douglas Bear,Stewart J. Anderson,Roy E. Smith,Charles E. Geyer,Eleftherios P. Mamounas,Bernard Fisher,Ann M. Brown,André Robidoux,Richard G. Margolese,Morton S. Kahlenberg,Soonmyung Paik,Atilla Soran,D. Lawrence Wickerham,Norman Wolmark +13 more
TL;DR: The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences.
Journal ArticleDOI
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
Soonmyung Paik,John Bryant,Chanheun Park,Bernard Fisher,Elizabeth Tan-Chiu,David Hyams,Edwin R. Fisher,Marc E. Lippman,D. Lawrence Wickerham,Norman Wolmark +9 more
TL;DR: The hypothesis of a preferential benefit from doxorubicin in patients with erbB-2-positive breast cancer is supported, with data supporting this hypothesis after a mean time of 13.5 years.
Journal ArticleDOI
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick,Ivana Sestak,Bernardo Bonanni,Joseph P. Costantino,Steve Cummings,Andrea Decensi,Mitch Dowsett,John F. Forbes,Leslie G. Ford,Andrea Z. LaCroix,John L. Mershon,Bruce H. Mitlak,Trevor J. Powles,Umberto Veronesi,Victor G. Vogel,D. Lawrence Wickerham +15 more
TL;DR: For all SERMs, incidence of invasive oestrogen (ER)-positive breast cancer was reduced both during treatment and for at least 5 years after completion.